Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6700195 | 0.99 | ITGB3 (0.55) | ITGB3ITGA2BFAAHHTR2AHTR2C | |
| SCHEMBL6698553 | 0.91 | FAAH (0.54) | ITGB3ITGA2BFAAHCHRM4CHRM3 | |
| Citric Acid SCHEMBL6698618 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BFAAHHTR2AHTR2C | |
| SCHEMBL6700094 | 0.85 | ITGB3 (0.63) | ITGB3ITGA2BHTR2AHTR2CHTR2B | |
| SCHEMBL6647499 | 0.84 | CYP17A1 (0.51) | FAAHCYP17A1CYP21A2CYP11B1 | |
| SCHEMBL7239878 | 0.84 | FAAH (0.49) | ITGB3ITGA2BFAAHCHRM4CHRM3 | |
| SCHEMBL27760391 | 0.84 | OPRM1 (0.58) | FAAHCHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL6700203 | 0.83 | CYP17A1 (0.50) | FAAHCYP17A1CYP21A2CYP11B1 | |
| SCHEMBL6863340 | 0.82 | DRD4 (0.64) | FAAHCYP17A1CYP21A2CYP11B1CHRM4 | |
| SCHEMBL6698987 | 0.82 | ITGB3 (0.60) | ITGB3ITGA2BFAAHHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1131222-C | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2003-12-17 | — | — | CN | claimed |
| WO-2003048121-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | claimed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | claimed |
| CN-1334808-A | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2002-02-06 | — | — | CN | claimed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| CN-1131222-C | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2003-12-17 | — | — | CN | disclosed |
| WO-2003048121-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| CN-1334808-A | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2002-02-06 | — | — | CN | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | ITGB3 4265/4885ITGA2B 3776/4885FAAH 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.